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The role of multiple developmental signaling pathways in the regulation of hematopoiesis has been contro-
versial. In this issue of Cell Stem Cell, two separate reports (Hofmann et al., 2009; Gao et al., 2009) examine
whether the Hedgehog signaling pathway modulates normal adult hematopoietic stem cells and blood
formation.
The role of developmental signaling path-
ways such as Wnt, Notch, and Hedgehog
(Hh) in adult tissue homeostasis and, in
particular, the regulation of adult stem
cells hasbeen thesubject of intensestudy.
Hematopoiesis has served as a model
system to study normal stem cells, and
all three of these pathways have been
found to affect the self-renewal and
proliferation of hematopoietic stem cells
(HSCs). However, these data have not
been conclusive, and seemingly contra-
dictory results exist in the literature. Now,
two independent articles from theGilliland
and Aifantis laboratories report the unex-
pected finding that canonical Hh signaling
is dispensable for normal adult hemato-
poiesis (Hofmann et al., 2009; Gao et al.,
2009).
Hh signaling in mammals is initiated by
the binding of one of three closely related
ligands, Sonic Hh (Shh), Indian Hh (Ihh),
and Desert Hh (Dhh), to the cell-surface
receptor Patched (Ptch). Upon ligand
binding, the inhibitory activity of Ptch
on the positive transmembrane effector
Smoothened (Smo) is lost and ultimately
results in the modulation of activity of the
three zinc finger transcription factors,
Gli1, Gli2, and Gli3, at target promoters
(Taipale and Beachy, 2001). Each compo-
nent of this cascade is required for proper
Hh signal transduction. In this issue,
both Hofmann et al. (2009) and Gao et al.
(2009) report that hematopoiesis, periph-
eral blood counts, colony formation
in vitro, and stem and progenitor subset
frequencies areall normal after conditional
ablation of Smo. Furthermore, through
competitive and serial bonemarrow trans-
plants, the two groups also demonstrate
that Smo null HSCs exhibit no defects in
homing, engraftment, and long-term self-
renewal. Collectively, their findings indi-
cate that Hh signaling is dispensable for
hematopoietic function in mice.
In contrast, seemingly different results
fromprevious reports have led to alternate
conclusions. Initial studies reported that
Hh ligand induced theexpansionof human
HSCs in vitro (Bhardwaj et al., 2001) and is
required for definitive hematopoiesis in
zebrafish (Gering and Patient, 2005). A
subsequent report found that HSCs with
increased baseline Hh activity, modeled
using Ptch heterozygote (Ptch+/) mice,
displayed increased HSC proliferation re-
sulting in eventual exhaustion, indicated
by the loss of long-term engraftment
after bone marrow transplantation (Trow-
bridge et al., 2006). However, using the
same murine model, Dierks et al. recently
reported enhanced engraftment of bone
marrow from Ptch+/ mice (Dierks et al.,
2008). In the same paper, this group also
reported no loss of long-term HSC
engraftment in mice homozygous for a
germline deletion of Smo. More recently,
the opposite conclusion was drawn by
Zhao et al., who observed a profound
loss of HSC function after conditional
deletion of Smo (Zhao et al., 2009).
Conflicting findings regarding the role
of Hh in normal hematopoiesis could
be due to interspecies differences or
the specific component of the signaling
pathway being modified, yet these expla-
nations do not account for the variable
results observed following Smo deletion
in mice. Although germline loss of Smo
is embryonically lethal, the mice live
beyond the point at which definitive
HSCs are specified in the fetal liver, which
allows the cells to be removed and trans-
planted into adult hosts as carried out by
Dierks et al. (2008). HSCs derived from
Smo wild-type and null fetal liver exhibit
identical function, proving that Smo is
not required during the specification of
definitive hematopoiesis in the embryo.
Unlike Dierks et al., Zhao et al. and the
two new papers fromGilliland and Aifantis
all used conditional Smo alleles. Zhao
et al. used the vav-Cre mouse to drive
inactivation of Smo in hematopoietic
tissues, given that the vav transcriptional
elements are active in all hematopoietic
and endothelial tissues from embryonic
life onward. In contrast, both Hofmann
et al. (2009) and Gao et al. (2009) used
the interferon inducible Mx1-Cre allele to
inactivate Smo in the hematopoietic
tissues of adult mice. It is possible that
Smo specifies certain HSC characteris-
tics during embryonic development that
have important consequences during
adult life. This hypothesis might explain
the results of Zhao et al. (2009), who
observed a dramatic defect in HSC
function, while the two current groups
saw no differences after transplantation.
However, if embryonic activity of Smo
was critical for adult HSC function, one
would expect that Dierks et al. would
have also seen an HSC defect, since
they used mice with a germline deletion
of Smo.
Similarly discordant results have been
reported following conditional deletion of
b-catenin using vav-Cre or Mx1-Cre
mice, where the former led to significant
HSC defects and the latter revealed no
functional deficits (reviewed in Malhotra
and Kincade, 2009). These results
suggest that the Mx1-Cre and vav-Cre
models may not be comparable when
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studying HSC function. While both vav-
Cre and Mx1-Cre appear to be active in
the most primitive stem cell compart-
ment, vav-Cre is also active in endothelial
cells, which are found in close proximity to
many primitive HSCs (reviewed in this
issue by Garrett and Emerson, 2009).
The two current papers from Gilliland
and Aifantis show that Smo is not neces-
sary for the cell-autonomous function
of HSCs in mice, but it is possible that
Hh may influence hematopoiesis through
more-complicated cell-niche signaling
interactions, as has been observed in
other tissues (Takashima et al., 2008). It
is likely that the inherent complexity of
these pathways, promiscuous ligand
receptor interactions, functional redun-
dancy, and possible crosstalk between
the signaling cascades also contribute
to the range of experimental results
obtained.
Similar to normal hematopoiesis, data
regarding Hh signaling in various leuke-
mias has also been inconsistent. Both
Zhao et al. (2009) and Dierks et al. (2008)
found that that Hh signaling is required
for the development of a chronic myeloid
leukemia-like disease induced by BCR-
ABL. However, in the two reports pre-
sented in this issue, Smo was found to
be dispensable for the development of
acute leukemias induced by either the
MLL-AF9 fusion gene or by an activated
form of Notch-1. It is likely that the role
of Hh in malignant hematopoiesis is
highly contextual and dependent upon
the specifics of the model being used.
Furthermore, aberrant pathway activa-
tion, noncanonical signal transduction,
and tumor-microenvironment interactions
have all been observed, further compli-
cating our understanding of Hh signaling
in cancer.
A wide variety of human cancers
display Hh pathway activity, and these
findings have spurred the development
of novel pathway inhibitors that antago-
nize Smo. Understanding Hh signaling
in hematopoiesis will likely inform the
optimal clinical use of these inhibitors in
terms of both patient selection and the
choice of other therapies to use in combi-
nation. However, it is also possible that
the clinical use of potent SMO inhibitors
will clarify the controversies surrounding
the role of Hh in hematopoiesis, since
their effects on human HSCs and progen-
itors can be evaluated directly in patients.
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